144 related articles for article (PubMed ID: 38307919)
1. Identification of EMT-associated prognostic features among grade II/III gliomas.
Yang W; Lin L; Lu T; Yu H; Zhang S
Sci Rep; 2024 Feb; 14(1):2822. PubMed ID: 38307919
[TBL] [Abstract][Full Text] [Related]
2. Identification of an epithelial-mesenchymal transition related long non-coding RNA (LncRNA) signature in Glioma.
Tao C; Luo H; Chen L; Li J; Zhu X; Huang K
Bioengineered; 2021 Dec; 12(1):4016-4031. PubMed ID: 34288803
[TBL] [Abstract][Full Text] [Related]
3. Optimized risk stratification strategy for glioma patients based on the feature genes of poor immune cell infiltration patterns.
Wan HT; Su ZJ; Guo ZS; Wen P; Hong XY
J Cancer Res Clin Oncol; 2023 Nov; 149(15):13855-13874. PubMed ID: 37535161
[TBL] [Abstract][Full Text] [Related]
4. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
Patil V; Mahalingam K
Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
[TBL] [Abstract][Full Text] [Related]
5. High expression of RAB43 predicts poor prognosis and is associated with epithelial-mesenchymal transition in gliomas.
Han MZ; Huang B; Chen AJ; Zhang X; Xu R; Wang J; Li XG
Oncol Rep; 2017 Feb; 37(2):903-912. PubMed ID: 28075478
[TBL] [Abstract][Full Text] [Related]
6. EMP3 as a prognostic biomarker correlates with EMT in GBM.
Li L; Xia S; Zhao Z; Deng L; Wang H; Yang D; Hu Y; Ji J; Huang D; Xin T
BMC Cancer; 2024 Jan; 24(1):89. PubMed ID: 38229014
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
8. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
[TBL] [Abstract][Full Text] [Related]
10. Rab27a was identified as a prognostic biomaker by mRNA profiling, correlated with malignant progression and subtype preference in gliomas.
Wang H; Zhao Y; Zhang C; Li M; Jiang C; Li Y
PLoS One; 2014; 9(2):e89782. PubMed ID: 24587032
[TBL] [Abstract][Full Text] [Related]
11. A Prognostic Signature for Lower Grade Gliomas Based on Expression of Long Non-Coding RNAs.
Kiran M; Chatrath A; Tang X; Keenan DM; Dutta A
Mol Neurobiol; 2019 Jul; 56(7):4786-4798. PubMed ID: 30392137
[TBL] [Abstract][Full Text] [Related]
12. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
13. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
14. Identification of WHO II/III Gliomas by 16 Prognostic-related Gene Signatures using Machine Learning Methods.
Wu YM; Sa Y; Guo Y; Li QF; Zhang N
Curr Med Chem; 2022; 29(9):1622-1639. PubMed ID: 34455959
[TBL] [Abstract][Full Text] [Related]
15. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
16. Integrating bulk and single-cell RNA sequencing data reveals epithelial-mesenchymal transition molecular subtype and signature to predict prognosis, immunotherapy efficacy, and drug candidates in low-grade gliomas.
Wang C; He Z
Front Pharmacol; 2023; 14():1276466. PubMed ID: 38053842
[No Abstract] [Full Text] [Related]
17. Weighted gene correlation network analysis identifies microenvironment-related genes signature as prognostic candidate for Grade II/III glioma.
Li Y; Deng G; Zhang H; Qi Y; Gao L; Tan Y; Hu P; Wang Y; Liu B; Chen Q
Aging (Albany NY); 2020 Nov; 12(21):22122-22138. PubMed ID: 33186124
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Notch1 oncogene by miR-139-5p inhibits glioma metastasis and epithelial-mesenchymal transition (EMT).
Li J; Li Q; Lin L; Wang R; Chen L; Du W; Jiang C; Li R
BMC Neurol; 2018 Aug; 18(1):133. PubMed ID: 30170559
[TBL] [Abstract][Full Text] [Related]
19. TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas.
Han MZ; Xu R; Xu YY; Zhang X; Ni SL; Huang B; Chen AJ; Wei YZ; Wang S; Li WJ; Zhang Q; Li G; Li XG; Wang J
J Exp Clin Cancer Res; 2017 Nov; 36(1):155. PubMed ID: 29110682
[TBL] [Abstract][Full Text] [Related]
20. Classification related to immunogenic cell death predicts prognosis, immune microenvironment characteristics, and response to immunotherapy in lower-grade gliomas.
Kuang Y; Jiang B; Zhu H; Zhou Y; Huang H; Li C; Zhang W; Li X; Cao Y
Front Immunol; 2023; 14():1102094. PubMed ID: 37153540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
